Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML - Novartis novartis.com Submitted by novartiscom2341 on June 2, 2024 at 2:48 AM in business No comments 58
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash - Novartis novartis.com Submitted by novartiscom2341 on February 6, 2024 at 9:55 PM in business No comments 58
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts - Novartis novartis.com Submitted by novartiscom2341 on February 1, 2024 at 6:04 AM in business No comments 57
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia - Novartis novartis.com Submitted by novartiscom2341 on January 9, 2024 at 6:22 AM in business No comments 53
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH - Novartis novartis.com Submitted by novartiscom2341 on December 7, 2023 at 1:43 AM in business No comments 47
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) - Novartis novartis.com Submitted by novartiscom2341 on October 31, 2023 at 6:50 AM in business No comments 30
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance - Novartis novartis.com Submitted by novartiscom2341 on October 25, 2023 at 5:05 AM in business No comments 10
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company - Novartis novartis.com Submitted by novartiscom2341 on October 5, 2023 at 5:08 AM in business No comments 52
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) - Novartis novartis.com Submitted by novartiscom2341 on October 3, 2023 at 6:25 AM in business No comments 49
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) - Novartis novartis.com Submitted by novartiscom2341 on September 25, 2023 at 5:21 AM in business No comments 10
Novartis signs agreement to divest 'front of eye' ophthalmology assets in line with focused strategy - Novartis novartis.com Submitted by novartiscom2341 on June 30, 2023 at 12:08 PM in business No comments 6